Ipertrofan (Mepartricin)

Mepartricin binds to parasite‑specific ion channels, especially glutamate‑gated chloride channels, causing an influx of chloride ions that hyperpolarizes the worm’s nerve and muscle cells, leading to paralysis and death. In the prostate, it modulates inflammatory pathways, reducing cytokine release and smooth‑muscle spasm.

The dosage of Ipertrofan is determined by the prescribing healthcare professional based on the specific infection, patient weight, age, and renal or hepatic function. Patients should follow the exact regimen provided by their doctor and not adjust the dose on their own.

Safety data for mepartricin in pregnancy are limited; it should only be used if the potential benefit outweighs any possible risk to the fetus. During breastfeeding, caution is advised because the drug may be secreted in breast milk, and a healthcare provider should evaluate the risk‑benefit balance.

To request Ipertrofan, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with older anthelmintics such as albendazole, mepartricin offers a broader spectrum against certain nematodes and may provide additional anti‑inflammatory benefits in chronic prostatitis. However, choice of therapy depends on the parasite species, resistance patterns, patient tolerance and clinical guidelines.

Ipertrofan should be stored at ambient temperature, preferably below 25 °C, in its original container to protect it from moisture, light and excessive heat. Keeping the product in a dry place helps maintain its potency throughout its shelf life.

Ipertrofan is taken orally, usually with a glass of water. The tablet or capsule should be swallowed whole unless the prescriber advises otherwise. Administration timing relative to meals may be specified by the healthcare provider to optimise absorption.

The most serious adverse reactions include severe allergic responses such as anaphylaxis, hepatotoxicity indicated by marked liver enzyme elevations, and rare skin conditions like Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience breathing difficulty, jaundice, or extensive skin blistering.

Ipertrofan is contraindicated in individuals with known hypersensitivity to mepartricin or any excipients, in patients with severe hepatic or renal impairment unless dose adjustments are made, and in pregnant women unless the potential benefit justifies the risk. Children under the approved age limit should also avoid use unless specifically directed by a physician.